Gilead’s Kite enters leukemia with Tecartus FDA approval, overlapping Novartis’ CAR-T rival Kymriah
Gilead Sciences’ Kite Pharma has expanded its second CAR-T cell therapy, Tecartus, into a leukemia market that overlaps a Novartis territory for Kymirah.
The FDA cle...
Continue Reading →
